CymaBay Therapeutics (CBAY) Getting Somewhat Positive Media Coverage, Report Shows

News headlines about CymaBay Therapeutics (NASDAQ:CBAY) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CymaBay Therapeutics earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.7701294308102 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of CymaBay Therapeutics (NASDAQ:CBAY) opened at $9.31 on Friday. The firm has a market cap of $390.39, a P/E ratio of -9.13 and a beta of 2.15. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.39 and a quick ratio of 7.39. CymaBay Therapeutics has a 52-week low of $1.46 and a 52-week high of $9.79.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). During the same quarter last year, the business posted ($0.25) EPS. research analysts predict that CymaBay Therapeutics will post -0.82 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on CBAY. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $16.00 target price on shares of CymaBay Therapeutics in a research note on Tuesday, September 26th. Zacks Investment Research raised shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Leerink Swann reiterated a “buy” rating and issued a $16.00 price target on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Oppenheimer set a $15.00 price target on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research report on Monday, October 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $14.50.

In other CymaBay Therapeutics news, Director Carl Goldfischer sold 18,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $8.66, for a total transaction of $155,880.00. Following the sale, the director now directly owns 9,000 shares in the company, valued at approximately $77,940. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kurt Von Emster sold 211,124 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $8.09, for a total transaction of $1,707,993.16. The disclosure for this sale can be found here. Insiders sold a total of 447,257 shares of company stock worth $3,730,862 over the last quarter. 15.10% of the stock is currently owned by corporate insiders.

WARNING: This article was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.com-unik.info/2017/12/24/cymabay-therapeutics-cbay-getting-somewhat-positive-media-coverage-report-shows.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

What are top analysts saying about CymaBay Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CymaBay Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit